Article Versions Notes

Xue J, Li B, Wang Y, Huang Z, Liu X, Guo C, Zheng Z, Liang N, Le X, Li S. Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis. Cancers. 2022; 14(19):4894. https://doi.org/10.3390/cancers14194894

Xue, Jianchao, Bowen Li, Yadong Wang, Zhicheng Huang, Xinyu Liu, Chao Guo, Zhibo Zheng, Naixin Liang, Xiuning Le, and Shanqing Li. 2022. "Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis" Cancers 14, no. 19: 4894. https://doi.org/10.3390/cancers14194894

Xue, J., Li, B., Wang, Y., Huang, Z., Liu, X., Guo, C., Zheng, Z., Liang, N., Le, X., & Li, S. (2022). Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis. Cancers, 14(19), 4894. https://doi.org/10.3390/cancers14194894